The Carcinogenic Potency Project

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (CAS 24554-26-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
ubl ubl ubl hmo lun sto ubl 4.25m,P,v 19.7m,v

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
sto ubl no test <9.77P

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   hmo = hematopoietic system. lun = lung. sto = stomach. ubl = urinary bladder. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. P = 100% of dosed animals had tumors at a target site in an experiment in this species. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments. < = For the only target site in the species, 100% of dosed animals had tumors. The value reported is the upper 99% confidence limit on TD50; no TD50 could be calculated because only summary data (not lifetable) were available. A TD50 value would be less than the reported upper confidence limit.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE  (FANFT) 24554-26-5
4260 H m syg eat 48w70 1077                          0    63.1mg                                          Croft;jnci,51,941-949;1973
 ubl mix e      noTD50   P<.0005 +  n.s.s. 9.77mg   0/20   23/23
 ubl sqc e      54.0mg   P<.003  +  23.2mg 238.mg   0/20    7/23
 for sqp e      83.8mg   P<.007  +  31.7mg 1.09gm   0/24    5/24
 liv tum e      no dre   P=1.       141.mg n.s.s.   0/24    0/24
 lun tum e      no dre   P=1.       141.mg n.s.s.   0/24    0/24
4261 M f cd1 eat 36w68 1601                          0    68.8mg                                       Dunsford;jnci,73,151-160;1984
 ubl tcc e      33.3mg   P<.0005 +  20.5mg 58.9mg   0/53   25/55
 ubl spt e      128.mg   P<.002  +  58.0mg 449.mg   0/53    8/55
 ubl sqc e      128.mg   P<.002  +  58.0mg 449.mg   0/53    8/55
 lun ade e      1.12gm   P<.6       148.mg n.s.s.   1/53    2/55
 liv tum e      no dre   P=1.       333.mg n.s.s.   0/53    0/55
 tba mix e      18.7mg   P<.0005    10.6mg 45.9mg  19/53   43/55
4262 M m cd1 eat 40w77 1601                          0    62.3mg
 ubl tcc e      30.5mg   P<.0005 +  19.5mg 51.4mg   0/55   30/56
 ubl spt e      97.1mg   P<.0005 +  49.9mg 230.mg   0/55   12/56
 ubl sqc e      250.mg   P<.009  +  95.0mg 6.08gm   0/55    5/56
 lun ade e      no dre   P=1.       298.mg n.s.s.   4/55    1/56
 liv hpc e      no dre   P=1.       298.mg n.s.s.   4/55    1/56
 tba mix e      21.5mg   P<.0005    12.6mg 47.6mg  17/55   43/56
4263 M f nmr gav 68w75 1771                          0    114.mg  115.mg  118.mg                         Berger;clet,31,311-318;1986
 for sqc esv    139.mg * P<.0005 +  89.7mg 232.mg   0/100  14/60    4/13   12/44
 for pam esv    164.mg * P<.0005 +  103.mg 285.mg   0/100  18/60    1/13    7/44
 stg mal esv    944.mg * P<.02      358.mg n.s.s.   0/100   5/60    0/13    0/44
 liv mal esv    2.39gm * P<.2       588.mg n.s.s.   0/100   0/60    0/13    2/44
 lun adc esv    no dre   P=1.       106.mg n.s.s.   1/100   0/60    0/13    0/44
 tba mal esv    59.5mg * P<.0005    40.0mg 103.mg  18/100  35/60    7/13   27/44
 tba ben esv    69.4mg * P<.0005    48.4mg 107.mg   4/100  32/60    5/13   18/44
4264 M f swi eat 46w53 1068                          0    106.mg                                       Erturk;canr,30,1309-1311;1970
 ubl tum        18.2mg   P<.0005 +  11.5mg 30.6mg   0/56   31/48
 --- leu        55.4mg   P<.03   +  23.4mg n.s.s.  15/56   23/48
 lun car        163.mg   P<.03   +  60.3mg n.s.s.   1/56    6/48
4265 M f swi eat 46w66 1076                          0    85.2mg                                        Cohen;canr,33,1593-1597;1973
 ubl tcc e      7.72mg   P<.0005 +  3.21mg 17.4mg   0/28   20/21
 lun alc e      86.4mg   P<.003     32.7mg 508.mg   0/28    5/21
 --- lle e      78.3mg   P<.02   +  29.4mg n.s.s.   1/28    6/21
 for sqp e      235.mg   P<.07   +  57.7mg n.s.s.   0/28    2/21
 liv tum e      no dre   P=1.       148.mg n.s.s.   0/28    0/21
 tba mix e      noTD50   P<.0005    n.s.s. 12.5mg   1/28   21/21
4266 M f swi eat 33w52 1118                          0    41.3mg                                        Cohen;canr,38,1398-1405;1978
 ubl car        19.8mg   P<.0005 +  9.28mg 57.1mg   0/30    9/30
 --- leu        47.6mg   P<.08      15.6mg n.s.s.   1/30    5/30
 lun ala        208.mg   P<.3       33.9mg n.s.s.   0/30    1/30
 liv tum        no dre   P=1.       63.8mg n.s.s.   0/30    0/30
4267 R m f34 eat 30w52 727                           0    .115mg  .231mg  1.15mg  2.31mg  11.5mg  23.1mg     Arai;jnci,62,1013-1016;
                                                                                                                                1979
 ubl mix e      1.31mg * P<.0005 +  .739mg 2.38mg   0/20    0/16    0/15    0/16    1/15   13/14   16/16
 ubl ppc e      5.92mg * P<.0005    3.09mg 13.4mg   0/20    0/16    0/15    0/16    0/15    4/14    9/16
 liv tum e      no dre   P=1.       55.8ug n.s.s.   0/20    0/16    0/15    0/16    0/15    0/14    0/16
4268 R m f34 eat  7m24 1575                          0    .115mg  .577mg  1.15mg  5.77mg  11.5mg  23.1mg   Arai;clet,18,261-269;1983
 ubl car        3.18mg Z P<.0005 +  2.25mg 4.56mg   0/40    0/40    0/40    0/40   34/40   39/40  (36/40)
4269 R m fis eat 72w72 1430                          0    80.0mg                                    Fukushima;canr,41,3100-3103;1981
 ubl car        noTD50   P<.0005 +  n.s.s. 24.4mg   0/27    8/8
4270 R m fis eat 24m24 1574                          0    2.00mg                                          Murasaki;carc,4,97-99;1983
 liv tum        no dre   P=1.       8.24mg n.s.s.   0/30    0/20
 ubl tum        no dre   P=1.       8.24mg n.s.s.   0/30    0/20
4271 R m fis eat 36w74 1657m                         0    38.9mg                                        Cohen;canr,39,1207-1217;1979
 ubl car        4.51mg   P<.0005 +  1.85mg 10.3mg   0/42   19/20
 ubl ivc        9.74mg   P<.0005    4.99mg 21.5mg   0/42   15/20
 ubl nvc        60.5mg   P<.003     20.8mg 378.mg   0/42    4/20
 liv hnd        263.mg   P<.2       42.8mg n.s.s.   0/42    1/20
4272 R m fis eat 77w77 1657n                         0    80.0mg
 ubl car        9.87mg   P<.0005 +  5.36mg 17.5mg   0/42   40/42
 ubl ivc        18.1mg   P<.0005    11.3mg 30.5mg   0/42   34/42
 ubl nvc        195.mg   P<.004     79.4mg 1.19gm   0/42    6/42
 liv tum        no dre   P=1.       380.mg n.s.s.   0/42    0/42
4273 R f sda eat 46w63 1124                          0    68.6mg                                       Erturk;canr,27,1998-2002;1967
 ubl mix        5.07mg   P<.0005 +  2.24mg 10.3mg   0/30   29/30
4274 R f sda eat 26w70 1125m                         0    34.9mg                                       Erturk;canr,29,2219-2228;1969
 ubl mix er     noTD50   P<.0005 +  n.s.s. 4.81mg   0/34   30/30
 ubl tcc er     noTD50   P<.0005 +  n.s.s. 5.30mg   0/27   24/24
 ubl ppc er     48.6mg   P<.003  +  19.8mg 234.mg   0/34    6/30
4275 R f sda eat 46w70 1125n                         0    61.8mg
 ubl mix er     noTD50   P<.0005 +  n.s.s. 8.63mg   0/34   29/29
 ubl tcc er     noTD50   P<.0005 +  n.s.s. 9.56mg   0/27   23/23
 ubl ppc er     82.7mg   P<.003  +  33.6mg 383.mg   0/34    6/29
4276 R m sda eat 26w52 1125m                         0    37.6mg
 ubl tcc er     noTD50   P<.0005 +  n.s.s. 3.99mg   0/30   15/15
4277 R m sda eat 46w52 1125n                         0    66.5mg
 ubl tcc er     noTD50   P<.0005 +  n.s.s. 6.07mg   0/30   20/20
4278 R f wis eat 34w52 1123                          0    62.7mg                                           Adolphs;urre,6,19-27;1978
 ubl tcc er     noTD50   P<.0005 +  n.s.s. 4.76mg   0/15   30/30
Mutagenicity in Salmonella: positive
SMILES Code for N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide: [O-][N+](=O)C1=CC=C(O1)C2=CSC(=N2)NC=O
InChI Code for N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide: InChI=1/C8H5N3O4S/c12-4-9-8-10-5(3-16-8)6-1-2-7(15-6)11(13)14/h1-4H,(H,9,10,12)
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007